Skip to content
C79C79C79

Drawing based on the label description. No photo yet.

“60 mg, white to off-white, oval shaped film coated tablet debossed with "C79" on one side and plain on the other side”

C79 pill

Pill with imprint C79 is white, oval, 12 mm and has been identified as Raloxifene Hydrochloride 60 mg. It is used for osteoporosis (weak bones). It is supplied by Cadila Pharmaceuticals Limited.

Raloxifene Hydrochloride 60 mg

Imprint
C79
Strength
60 mg
Used for
Osteoporosis (weak bones)
Color
White
Shape
Oval
Size
12 mm
Score
No score line
Form
Tablet, coated
Manufacturer
Cadila Pharmaceuticals Limited
Drug class
Estrogen modulator
NDC
71209-082, 71209-082-01, 71209-082-05, 71209-082-13, 71209-082-11, 72241-010, 72241-010-22, 72241-010-05, 72241-010-13, 72241-010-11, 50090-6177, 50090-6177-1, 72162-2418, 72162-2418-0, 72162-2418-1, 72162-2418-3

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Raloxifene pills and guides

What is Raloxifene used for?

Raloxifene is used for osteoporosis (weak bones).

Medicine type
Estrogen modulator
Official uses from the US prescribing label

Treatment and Prevention of Osteoporosis in Postmenopausal Women

EVISTA is indicated for the treatment and prevention of osteoporosis in postmenopausal women.

Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis

EVISTA is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis.

Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women at High Risk of Invasive Breast Cancer

EVISTA is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.

The effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years. Twenty-seven percent of the participants received drug for 5 years. The long-term effects and the recommended length of treatment are not known.

High risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (LCIS) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer ≥1.66% (based on the modified Gail model). Among the factors included in the modified Gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. Healthcare professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-800-545-5979. Currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.

After an assessment of the risk of developing breast cancer, the decision regarding therapy with EVISTA should be based upon an individual assessment of the benefits and risks.

EVISTA does not eliminate the risk of breast cancer. Patients should have breast exams and mammograms before starting EVISTA and should continue regular breast exams and mammograms in keeping with good medical practice after beginning treatment with EVISTA.

Important Limitations of Use for Breast Cancer Risk Reduction

  • There are no data available regarding the effect of EVISTA on invasive breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of EVISTA.
  • EVISTA is not indicated for the treatment of invasive breast cancer or reduction of the risk of recurrence.
  • EVISTA is not indicated for the reduction in the risk of noninvasive breast cancer.

From the FDA-approved label on DailyMed (published Sep 02, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows C79 and the other side is plain.
  • It is white, oval, 12 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Raloxifene Hydrochloride

Inactive: Crospovidone, Hypromelloses, Lactose Monohydrate, Anhydrous Lactose, Magnesium Stearate, Polyethylene Glycol 400, Polysorbate 80, Povidone, Titanium Dioxide

Also distributed by

Modavar Pharmaceuticals LLC, A-S Medication Solutions, Bryant Ranch Prepack

Other pills with imprint C 79

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Raloxifene pills